READY-TO-USE KITS

ReadyCell Products

Our cell-based kits maximize efficacy and safety testing of new molecular entities during preclinical drug discovery and development.

Download catalog

Worldwide shipments to any location at room temperature thanks to our technology.

Products conceived according to main regulatory agencies’ requirements.

Free consultation and technical support during the assay and in bio-analytics.

READY-TO-USE MODELS

Available Kits

Caco-2 cell Kits

- - - CacoReady
    - CacoGoblet

MDCKII cell Kits

HEK293 cell Kits

Reagents

ReadyCell solutions: CACOREADY AND CACOGOBLET

Caco-2 cell Kits

Request user manual

CacoReady, your one-step Caco-2 solution

24 or 96 transwell insert plates seeded with 21 days differentiated and polarized Caco-2 cells. This cell model is considered to be the gold standard for assessing intestinal permeability of new oral drugs in in vitro preclinical studies, according to leading regulatory agencies.

Download booklet

CATALOG #: DESCRIPTION

KRECE-CCR01: CacoReady 24 Transwell
KRECE-CCR02: CacoReady 24 Well (without transwell)
KRECE-CCR04: CacoReady 24 Well (individual transwell)
KRECE-CCR50: CacoReady 96 Transwell
KRECE-CCR51: CacoReady 96 Well (without transwell)

See the characteristics of each format.

Drug permeability by passive diffusion and/or active transport through a physiologically relevant barrier.
Relevant barrier for the active transport of drugs through the Blood Brain Barrier.
Carrier-mediated transport mechanisms.
Drug toxicity.

All resources

Cui, Y., et al (2024) Azetidines Kill Multidrug-Resistant Mycobacterium tuberculosis without Detectable Resistance by Blocking Mycolate Assembly. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01643

Truffin, D., et al (2023). Polyols Permeability on Caco-2 Cells and Their Effects on Transport of Low-Permeability Drugs. Future Pharmacol. 229-237. https://doi.org/10.3390/futurepharmacol3010016

Moi, D., et al (2023). Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer. Eur J Med Chem. 2023 Aug 16;260:115730. doi: 10.1016/j.ejmech.2023.115730. Epub ahead of print. PMID: 37633202.

Novak, A., et al. (2022). Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation. Journal of Medicinal Chemistry, acs.jmedchem.2c01446.

Aquila, G., et al. (2022). Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia. Pharmaceutics, 14(7), 1507.

Pankiewicz, P., et al. (2021). Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists. Pharmaceuticals (Basel, Switzerland), 14(8), 704.

Denaro, M., Smeriglio, A., & Trombetta, D. (2021). Antioxidant and Anti-Inflammatory Activity of Citrus Flavanones Mix and Its Stability after In Vitro Simulated Digestion. Antioxidants (Basel, Switzerland), 10(2), 140.

Yeste, S., et al. (2020). Preliminary in Vitro Assessment of the Potential of EST64454, a Sigma-1 Receptor Antagonist, for Pharmacokinetic Drug–Drug Interactions. Biological and Pharmaceutical Bulletin, 2020 Vol. 43:1 p. 68-76.

Aubets J, Jansat J-M, Salva M, et al. (2019). No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter. Pharmacol Res Perspect. 2019;e00540.

Guardiola et al. (2018). Targeted Covalent Inhibition of Prolyl Oligopeptidase (POP): Discovery of Sulfonylfluoride Peptidomimetics. Cell Chemical Biology 25, 1031–1037.

Kenzaoui, B.H., Vilà, M., Juillerat-Jeanneret, L. (2012). Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomedicine. 2012; 7: 1275–1286. doi: 10.2147/IJN.S26865.

ICH M12 Drug Interaction Studies, 2022.

FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

EMA Guideline on Investigation of Drug Interactions, 2012.

PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.

Request user manual

A secreting mucus intestinal barrier

24 transwell insert plates seeded with 21 days differentiated and polarized Caco-2 and HT-29 cells with an absorptive and mucus-secreting phenotype, respectively. This co-culture allows evaluating the in vitro intestinal absorption of drug targets at a barrier physiologically closer to the intestinal epithelium. In addition, their responsiveness to inflammatory mediators provides valuable information on the efficacy of anti-inflammatory drugs.

Download booklet

CATALOG #: DESCRIPTION

KRECE-CCG01: CacoGoblet 24 Transwell
KRECE-CCG02: CacoGoblet 24 Well (individual transwell)

See the characteristics of each format.

Drug permeability by passive diffusion and/or active transport through a physiologically relevant barrier.
Carrier-mediated transport mechanisms.
Drug toxicity.
Anti-inflammatory drug testing.

All resources

Ma, L., Tu, H., & Chen, T. (2023). Postbiotics in Human Health: A Narrative Review. Nutrients, 15(2), 291.

Esquena-Moret, J. (2022). A Review of Xyloglucan: Self-Aggregation, Hydrogel Formation, Mucoadhesion and Uses in Medical Devices. Macromol, 2(4), 562–590.

Milani, N., et al. (2022). Application of a gut–liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil. Lab On A Chip, 22(15), 2853-2868.

Ortega-Anaya, J., et al. (2021). Milk fat globule membrane phospholipids modify adhesion of Lactobacillus to mucus-producing Caco-2/Goblet cells by altering the cell envelope. Food Research International. 146. 110471.

Servi, B., Ranzini, F. (2017). Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet cells. Future Microbiology, vol. 12, no. 16.

Fraile, B., et al. (2017). Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies. Future Microbiology, vol. 12, no. 8.

Kenzaoui, B.H., Vilà, M., Juillerat-Jeanneret, L. (2012). Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomedicine. 2012; 7: 1275–1286. doi: 10.2147/IJN.S26865.

ICH M12 Drug Interaction Studies, 2022.

FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

EMA Guideline on Investigation of Drug Interactions, 2012.

PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.

ReadyCell solutions: PREADYPORT

MDCKII cell Kits

Request user manual

PreadyPort, a relevant barrier for passive diffusion

24 and 96 transwell insert plates cultured with the 12 days differentiated MDCKII parental cell line. A reference in vitro model to evaluate passive permeation of orally administered drugs.

Download booklet

CATALOG #: DESCRIPTION

KRECE-CTR01: PreadyPort-CTRL (24 Transwell)
KRECE-CTR50: PreadyPort-CTRL (96 Transwell)

See the characteristics of each format.

Assaying drug permeability by passive diffusion
through a physiologically relevant barrier.
Drug permeability by passive diffusion through the Blood Brain Barrier.
Negative control for PreadyPort Kits overexpressing the MDR1
and/or BCRP efflux transporter.

All resources

Miyamoto, R., et al. (2019). The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein. Journal of Pharmaceutical Sciences, Vol. 108, Issue 3, pp. 1085-1089. https://doi.org/10.1016/j.xphs.2018.10.012.

Aubets, J., Jansat, J-M., Salva, M., et al. (2019). No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter. Pharmacol Res Perspect. 2019;e00540. DOI: 10.1002/prp2.540.

Mukkavilli, R., Jadhav, G., Vangala, S. (2017). Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines. Current Pharmaceutical Biotechnology, Vol. 18, No. 14, pp. 1151-1158(8). https://doi.org/10.2174/1389201019666180308091855.

ICH M12 Drug Interaction Studies, 2022.

FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

EMA Guideline on Investigation of Drug Interactions, 2012.

PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.

Request user manual

P-gp, an efflux transporter pump

24 or 96 transwell insert plates cultured with 12 days differentiated MDR1-overexpressing MDCKII cells. The MDR1 efflux transporter has an ubiquitous tissue distribution, with a critical role in intestinal absorption, biliary and urinary excretion of drugs and in the entry of active molecules into the central nervous system.

Download booklet

CATALOG #: DESCRIPTION

KRECE-CTR01: PreadyPort-CTRL (24 Transwell)
KRECE-CTR50: PreadyPort-CTRL (96 Transwell)
KRECE-MDR01: PreadyPort-MDR1 (24 Transwell)
KRECE-MDR02: PreadyPort-MDR1/CTRL 1:1 (24 Transwell)
KRECE-MDR50: PreadyPort-MDR1 (96 Transwell)
KRECE-MDR51: PreadyPort-MDR1/CTRL 1:1 (96 Transwell)

See the characteristics of each format.

MDR1 substrates, inhibitors and inducers.
MDR1 transporter-based drug-drug interactions (concomitantly administered drugs).
Drug permeability by passive diffusion through a physiologically relevant barrier.
Drug permeability by passive diffusion and MDR1 transporter through the Blood Brain Barrier.

All resources

Miyamoto, R., et al. (2019). The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein. Journal of Pharmaceutical Sciences, Vol. 108, Issue 3, pp. 1085-1089. https://doi.org/10.1016/j.xphs.2018.10.012.

Aubets, J., Jansat, J-M., Salva, M., et al. (2019). No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter. Pharmacol Res Perspect. 2019;e00540. DOI: 10.1002/prp2.540.

Mukkavilli, R., Jadhav, G., Vangala, S. (2017). Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines. Current Pharmaceutical Biotechnology, Vol. 18, No. 14, pp. 1151-1158(8). https://doi.org/10.2174/1389201019666180308091855.

ICH M12 Drug Interaction Studies, 2022.

FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

EMA Guideline on Investigation of Drug Interactions, 2012.

PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.

Request user manual

BCRP, an ATP-binding cassette (ABC) transporter protein

24 or 96 transwell insert plates cultured with 12 days differentiated BCRP-overexpressing MDCKII cells. BCRP is a high-capacity efflux transporter with broad substrate specificity. It is located in the apical cell membrane of barrier tissues and excretory organs.

Download booklet

CATALOG #: DESCRIPTION

KRECE-CTR01: PreadyPort-CTRL (24 Transwell)
KRECE-CTR50: PreadyPort-CTRL (96 Transwell)
KRECE-BCP01: PreadyPort-BCRP(24 Transwell)
KRECE-BCP02: PreadyPort-BCRP/CTRL 1:1 (24 Transwell)
KRECE-BCP50: PreadyPort-BCRP(96 Transwell)
KRECE-BCP51: PreadyPort-BCRP/CTRL 1:1 (96 Transwell)

See the characteristics of each format.

BCRP substrates, inhibitors and inducers.
BCRP transporter-based drug-drug interactions (concomitantly administered drugs).
Drug permeability by passive diffusion through a physiologically relevant barrier.

All resources

Miyamoto, R., et al. (2019). The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein. Journal of Pharmaceutical Sciences, Vol. 108, Issue 3, pp. 1085-1089. https://doi.org/10.1016/j.xphs.2018.10.012.

Mukkavilli, R., Jadhav, G., Vangala, S. (2017). Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines. Current Pharmaceutical Biotechnology, Vol. 18, No. 14, pp. 1151-1158(8). https://doi.org/10.2174/1389201019666180308091855.

ICH M12 Drug Interaction Studies, 2022.

FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

EMA Guideline on Investigation of Drug Interactions, 2012.

PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.

CUSTOM MADE PLATES

Set up your PreadyPort and PreadyTake plates with several clones cultures

Customize your 24-well and 96-well plates by combining MDCKII cells or HEK293 cells overexpressing efflux and uptake transporters respectively, according to the assay requirements.

ReadyCell solutions: PREADYTAKE

HEK293 cell Kits

Request user manual

A key transporter for renal and biliary excretion

96 multiwell insert plates with differentiated MATE1-overexpressing HEK293 cells. Drug-transporter interactions involving MATE1 may compromise drug renal clearance and biliary excretion.

Download booklet

CATALOG #: DESCRIPTION

KRECE-HEK50: PreadyTake-CTRL (96 Multiwell)
KRECE-MAT50: PreadyTake-MATE1 (96 Multiwell)
KRECE-MAT51: PreadyTake-MATE1/CTRL 1:1 (96 Multiwell)

MATE1 substrates, inhibitors and inducers.
MATE1 transporter-based drug-drug interactions (concomitantly administered drugs).
Competitive inhibition (unexpected drug elimination).

All resources

ICH M12 Drug Interaction Studies, 2022.

FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

EMA Guideline on Investigation of Drug Interactions, 2012.

PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.

Request user manual

OCT2 for renal clearance

96 multiwell insert plates with differentiated OCT2-overexpressing HEK293 cells. The OCT2 transporter carries a wide range of different solutes across biological membranes being especially relevant for those drugs that are renally excreted.

Download booklet

CATALOG #: DESCRIPTION

KRECE-HEK50: PreadyTake-CTRL (96 Multiwell)
KRECE-OCT50: PreadyTake-OCT2 (96 Multiwell)
KRECE-OCT51: PreadyTake-OCT2/CTRL 1:1 (96 Multiwell)

OCT2 substrates, inhibitors and inducers.
Compound interactions (concomitantly administered drugs).
Competitive inhibition (unexpected drug elimination).

All resources

ICH M12 Drug Interaction Studies, 2022.

FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

EMA Guideline on Investigation of Drug Interactions, 2012.

PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.

Request user manual

The hepatic polypeptide transporter 1B3

96 multiwell insert plates with differentiated HEK 293 cells expressing OATP1B3 as well as the parental cell line. Because of these transporters’ prominent expression on the sinusoidal membrane of hepatocytes, OATP1B3 represents a critical mechanism for the uptake of drugs into the liver.

Download booklet

CATALOG #: DESCRIPTION

KRECE-HEK50: PreadyTake-CTRL (96 Multiwell)
KRECE-OB350: PreadyTake-OATP1B3 (96 Multiwell)
KRECE-OB351: PreadyTake-OATP1B3/CTRL 1:1 (96 Multiwell)

OATP1B3 substrates, inhibitors and inducers
Compound interactions (concomitantly administered drugs)
Competitive inhibition (unexpected drug elimination)

All resources

ICH M12 Drug Interaction Studies, 2022.

FDA Guidance for Industry: In Vitro Drug Interactions Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions, 2020.

EMA Guideline on Investigation of Drug Interactions, 2012.

PMDA Guideline on drug interaction for drug development and appropriate provision of information, 2018.

ReadyCell solutions

Supplementary Reagents

At ReadyCell we provide all necessary and appropriate solutions for each assay to efficiently ease your screening.

Get A Free Consultation & Estimate

Rely on specialized support from an experienced team and get the highest quality of kits for a perfect replicability of in vitro assays.

Cookie	Duration	Description
__hssrc	session	This cookie is set by Hubspot whenever it changes the session cookie. The __hssrc cookie set to 1 indicates that the user has restarted the browser, and if the cookie does not exist, it is assumed to be a new session.
_GRECAPTCHA	5 months 27 days	This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
__cf_bm	30 minutes	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
__hssc	30 minutes	HubSpot sets this cookie to keep track of sessions and to determine if HubSpot should increment the session number and timestamps in the __hstc cookie.

Cookie	Duration	Description
__hstc	5 months 27 days	This is the main cookie set by Hubspot, for tracking visitors. It contains the domain, initial timestamp (first visit), last timestamp (last visit), current timestamp (this visit), and session number (increments for each subsequent session).
_clck	1 year	Microsoft Clarity sets this cookie to retain the browser's Clarity User ID and settings exclusive to that website. This guarantees that actions taken during subsequent visits to the same website will be linked to the same user ID.
_clsk	1 day	Microsoft Clarity sets this cookie to store and consolidate a user's pageviews into a single session recording.
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.
_ga_ETHVYTQS6W	2 years	This cookie is installed by Google Analytics.
_gat_gtag_UA_*	1 minute	Google Analytics sets this cookie to store a unique user ID.
_gat_gtag_UA_137693070_1	1 minute	Set by Google to distinguish users.
_gcl_au	3 months	Provided by Google Tag Manager to experiment advertisement efficiency of websites using their services.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
CLID	1 year	Microsoft Clarity set this cookie to store information about how visitors interact with the website. The cookie helps to provide an analysis report. The data collection includes the number of visitors, where they visit the website, and the pages visited.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
hubspotutk	5 months 27 days	HubSpot sets this cookie to keep track of the visitors to the website. This cookie is passed to HubSpot on form submission and used when deduplicating contacts.
MR	7 days	This cookie, set by Bing, is used to collect user information for analytics purposes.
SM	session	Microsoft Clarity cookie set this cookie for synchronizing the MUID across Microsoft domains.

Cookie	Duration	Description
ANONCHK	10 minutes	The ANONCHK cookie, set by Bing, is used to store a user's session ID and verify ads' clicks on the Bing search engine. The cookie helps in reporting and personalization as well.
IDE	1 year 24 days	Google DoubleClick IDE cookies are used to store information about how the user uses the website to present them with relevant ads and according to the user profile.
MUID	1 year 24 days	Bing sets this cookie to recognise unique web browsers visiting Microsoft sites. This cookie is used for advertising, site analytics, and other operations.
test_cookie	15 minutes	The test_cookie is set by doubleclick.net and is used to determine if the user's browser supports cookies.
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt.innertube::nextId	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.
yt.innertube::requests	never	YouTube sets this cookie to register a unique ID to store data on what videos from YouTube the user has seen.

Cookie	Duration	Description
et_pb_ab_view_page_774	session	No description
VISITOR_PRIVACY_METADATA	5 months 27 days	Description is currently not available.